Beyond Amyloid: Small Molecule Inflammasome Modulators
- Showing that inflammasome modulating small molecule reverses memory loss even with amyloid still present, opening a non amyloid treatment path and diversifying therapeutic risk after 30 years of single target focus
- Leveraging blood biomarkers like p Tau217 to provide objective read outs of anti inflammatory efficacy, enabling faster, smaller proof of concept studies
- Delivering orally bioavailable small molecules that bypass blood-brain barrier hurdles faced by antibodies, simplifying dosing and improving long term patient adherence